{"name":"Nuon Therapeutics, Inc.","slug":"nuon-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Combination 600","genericName":"Combination 600","slug":"combination-600","indication":"Phase 2 clinical trials for Combination 600 are ongoing for the treatment of [specific condition]","status":"phase_2"},{"name":"Combination - Tranilast and Allopurinol","genericName":"Combination - Tranilast and Allopurinol","slug":"combination-tranilast-and-allopurinol","indication":"Gout","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Combination - Tranilast and Febuxostat","genericName":"Combination - Tranilast and Febuxostat","slug":"combination-tranilast-and-febuxostat","indication":"Gout, Malignant hypertension","status":"phase_2"}]}],"pipeline":[{"name":"Combination 600","genericName":"Combination 600","slug":"combination-600","phase":"phase_2","mechanism":"Combination 600 is a combination of two or more drugs that work together to treat a specific condition.","indications":["Phase 2 clinical trials for Combination 600 are ongoing for the treatment of [specific condition]"],"catalyst":""},{"name":"Combination - Tranilast and Allopurinol","genericName":"Combination - Tranilast and Allopurinol","slug":"combination-tranilast-and-allopurinol","phase":"phase_2","mechanism":"Tranilast inhibits the activity of mast cells and platelets, while Allopurinol inhibits xanthine oxidase.","indications":["Gout","Allergic rhinitis"],"catalyst":""},{"name":"Combination - Tranilast and Febuxostat","genericName":"Combination - Tranilast and Febuxostat","slug":"combination-tranilast-and-febuxostat","phase":"phase_2","mechanism":"Tranilast is a selective inhibitor of PDGF receptors, while Febuxostat is a xanthine oxidase inhibitor.","indications":["Gout, Malignant hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":3},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}